CBD shows clinical promise for epilepsy and early signals for anxiety, psychosis, and addiction | Research

The takeaway

CBD has established clinical evidence for seizure disorders and childhood epilepsies, with promising but less mature evidence for anxiety, psychosis, Parkinson's quality of life, and addictive behaviors.

People interested in CBD for mental health conditions, neurological disorders, or understanding where the evidence actually stands.

CBD clinically effective for epilepsy; no human studies yet for depression or Alzheimer's

What the researchers found

CBD is safe, well-tolerated, and efficacious for several seizure disorders. It shows anxiolytic effects in social anxiety disorder and antipsychotic effects in schizophrenia. Parkinson's patients reported improved sleep and quality of life. No human studies existed for Alzheimer's or unipolar depression at the time of review.

Why it matters

This review maps the landscape of CBD research across neuropsychiatric conditions, clearly distinguishing where clinical evidence exists (epilepsy) from where only preclinical data supports therapeutic potential (depression, Alzheimer's).

The numbers in context

CBD demonstrated anti-epileptic, anti-oxidant, anti-inflammatory, antipsychotic, anxiolytic, and antidepressant properties in preclinical studies. Clinical efficacy confirmed for seizure disorders. CBD treatment alone was insufficient for Huntington's disease choreic movements.

How the study worked

Narrative review summarizing selected preclinical and clinical studies examining CBD effects across neuropsychiatric disorders including epilepsy, psychosis, anxiety, Parkinson's, Huntington's, addiction, Alzheimer's, and depression.

What this study cannot tell us

Narrative review with inherent selection bias in study inclusion. Many conditions discussed have only preclinical evidence. Sample sizes in existing clinical trials are generally small. Long-term safety data are limited.

How to read the evidence

Moderate: narrative review covering substantial preclinical and clinical literature, but non-systematic methodology.

When this study was published

Published in 2019.

The bigger picture

The gap between preclinical promise and clinical evidence for CBD is large for most neuropsychiatric conditions. While epilepsy has strong trial data, conditions like depression and Alzheimer's have zero human studies, making consumer claims about CBD for these conditions premature.

Questions still open

Will human trials confirm CBD's preclinical antidepressant effects? What is the optimal dosing for each neuropsychiatric condition? Can CBD be combined with existing treatments for synergistic benefit?

Common questions

What conditions does CBD actually have clinical evidence for?

As of this review, CBD has the strongest clinical evidence for seizure disorders and childhood epilepsies. There are smaller trials supporting effects on social anxiety disorder and schizophrenia. Depression and Alzheimer's have preclinical data only.

Is CBD safe for neuropsychiatric conditions?

Clinical studies have consistently found CBD to be safe and well-tolerated. However, most trials have been short-term, and long-term safety data for neuropsychiatric use are limited.

Read the original research

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.

Progress in molecular biology and translational science, 167, 25-75

View on PubMed ↗Publisher’s paper ↗

Citation

Elsaid, Sonja; Kloiber, Stefan; Le Foll, Bernard. (2019). Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.. Progress in molecular biology and translational science, 167, 25-75. https://doi.org/10.1016/bs.pmbts.2019.06.005